Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299044 | 0.83 | TP53 (0.44) | S1PR1MAPTGAAALDH1A1L3MBTL1 | |
| SCHEMBL10149941 | 0.83 | HTT (0.54) | MAPTRAB9AGAAMAPK1LMNA | |
| SCHEMBL13298982 | 0.78 | MAPT (0.41) | S1PR1MAPTRAB9AGAAMAPK1 | |
| SCHEMBL13299006 | 0.75 | ALDH1A1 (0.49) | MAPTRAB9AGAAMAPK1LMNA | |
| SCHEMBL10149723 | 0.75 | MAPT (0.41) | S1PR1MAPTRAB9AGAALMNA | |
| SCHEMBL23708632 | 0.74 | ALDH1A1 (0.62) | S1PR1MAPTRAB9AGAAMAPK1 | |
| SCHEMBL3321650 | 0.70 | ALDH1A1 (0.55) | MAPTRAB9AGAAMAPK1LMNA | |
| SCHEMBL10149834 | 0.70 | ALDH1A1 (0.55) | MAPTRAB9AGAAMAPK1LMNA | |
| SCHEMBL16157089 | 0.70 | MAPT (0.67) | MAPTRAB9AGAAMAPK1LMNA | |
| SCHEMBL23850431 | 0.69 | MAPT (0.57) | MAPTRAB9AGAAMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7648978-B2 | Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone | ANGION BIOMEDICA CORP. (US) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | HGF, IL2, IL2RA | S1PR1 344/4885MAPT 3078/4885RAB9A 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.